Showing results (51-60 of 74) with videos related to
Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2007
Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group studyTimothy W Synold, Chris H Takimoto, James H Doroshow, et al.Journal of Personalized Medicine|February 23, 2024
Clinical Impact of Comprehensive Molecular Profiling in Adolescents and Young Adults with SarcomaEden C Andrew, Jeremy Lewin, Jayesh Desai, et al.Cancer Medicine|May 19, 2025
Trends in Practice Patterns and Clinical Outcomes for Desmoid Tumors: A Large Single-Institutional Australian CohortJoseph Sia, Stephanie Tan, Narayan Mohanakrishnan, et al.Gynecologic Oncology|December 4, 2019
A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancerIgnace Vergote, Florian Heitz, Paul Buderath, et al.Internal Medicine Journal|April 3, 2018
Exploring the feasibility and utility of exome-scale tumour sequencing in a clinical settingBelinda Lee, Ben Tran, Arthur L Hsu, et al.BMJ Open|April 9, 2020
Developing a multivariable prediction model for functional outcome after reperfusion therapy for acute ischaemic stroke: study protocol for the Targeting Optimal Thrombolysis Outcomes (TOTO) multicentre cohort studyElizabeth Holliday, Thomas Lillicrap, Timothy Kleinig, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working GroupRamesh K Ramanathan, Merrill J Egorin, Chris H M Takimoto, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2007
Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal functionChris H Takimoto, Martin A Graham, Graham Lockwood, et al.JAMA Oncology|July 3, 2025
Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Nonrandomized Clinical TrialBo Gao, Matteo S Carlino, Michael Michael, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group StudyChris H Takimoto, Scot C Remick, Sunil Sharma, et al.Pageof 8